These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 18625222)

  • 1. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.
    Mollenhauer B; Cullen V; Kahn I; Krastins B; Outeiro TF; Pepivani I; Ng J; Schulz-Schaeffer W; Kretzschmar HA; McLean PJ; Trenkwalder C; Sarracino DA; Vonsattel JP; Locascio JJ; El-Agnaf OM; Schlossmacher MG
    Exp Neurol; 2008 Oct; 213(2):315-25. PubMed ID: 18625222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Boström F; Hansson O; Nielsen HM
    PLoS One; 2013; 8(1):e53250. PubMed ID: 23308173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous quantification of tau and α-synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls.
    Viodé A; Epelbaum S; Benyounes I; Verny M; Dubois B; Junot C; Fenaille F; Lamari F; Becher F
    Analyst; 2019 Oct; 144(21):6342-6351. PubMed ID: 31553333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.
    Oeckl P; Metzger F; Nagl M; von Arnim CA; Halbgebauer S; Steinacker P; Ludolph AC; Otto M
    Mol Cell Proteomics; 2016 Oct; 15(10):3126-3138. PubMed ID: 27507836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases.
    Llorens F; Kruse N; Schmitz M; Gotzmann N; Golanska E; Thüne K; Zejneli O; Kanata E; Knipper T; Cramm M; Lange P; Zafar S; Sikorska B; Liberski PP; Mitrova E; Varges D; Schmidt C; Sklaviadis T; Mollenhauer B; Zerr I
    Alzheimers Dement; 2017 Jun; 13(6):710-719. PubMed ID: 27870938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.
    Schmitz M; Villar-Piqué A; Llorens F; Gmitterová K; Hermann P; Varges D; Zafar S; Lingor P; Vanderstichele H; Demeyer L; Stoops E; Trojanowski JQ; Lee VM; Zerr I
    Mol Neurobiol; 2019 May; 56(5):3476-3483. PubMed ID: 30136097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
    Førland MG; Öhrfelt A; Oftedal LS; Tysnes OB; Larsen JP; Blennow K; Zetterberg H; Alves G; Lange J
    Clin Chem Lab Med; 2017 Feb; 55(2):254-260. PubMed ID: 27474841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy.
    Rong H; Jin L; Wei W; Wang X; Xi Z
    Seizure; 2015 Apr; 27():6-9. PubMed ID: 25891920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study.
    Unterberger U; Lachmann I; Voigtländer T; Pirker W; Berghoff AS; Flach K; Wagner U; Geneste A; Perret-Liaudet A; Kovacs GG
    Clin Neuropathol; 2014; 33(5):329-34. PubMed ID: 25131945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M; Londos E; Minthon L; Nielsen HM
    J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.